Suguru Yamamoto1, Jiayong Zhong2, Patricia G Yancey3, Yiqin Zuo4, MacRae F Linton5, Sergio Fazio6, Haichun Yang4, Ichiei Narita7, Valentina Kon8. 1. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan. 2. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA. 6. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Immunology and Microbiology, Vanderbilt University Medical Center, Nashville, TN, USA; Center for Preventive Cardiology at The Knight Cardiovascular Institute of Oregon Health and Science University, Portland, OR, USA. 7. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan. 8. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: valentina.kon@vanderbilt.edu.
Abstract
OBJECTIVE: Chronic kidney disease (CKD) amplifies atherosclerosis, which involves renin-angiotensin system (RAS) regulation of macrophages. RAS influences peroxisome proliferator-activated receptor-γ (PPARγ), a modulator of atherogenic functions of macrophages, however, little is known about its effects in CKD. We examined the impact of combined therapy with a PPARγ agonist and angiotensin receptor blocker on atherogenesis in a murine uninephrectomy model. METHODS: Apolipoprotein E knockout mice underwent uninephrectomy (UNx) and treatment with pioglitazone (UNx + Pio), losartan (UNx + Los), or both (UNx + Pio/Los) for 10 weeks. Extent and characteristics of atherosclerotic lesions and macrophage phenotypes were assessed; RAW264.7 and primary peritoneal mouse cells were used to examine pioglitazone and losartan effects on macrophage phenotype and inflammatory response. RESULTS: UNx significantly increased atherosclerosis. Pioglitazone and losartan each significantly reduced the atherosclerotic burden by 29.6% and 33.5%, respectively; although the benefit was dramatically augmented by combination treatment which lessened atherosclerosis by 55.7%. Assessment of plaques revealed significantly greater macrophage area in UNx + Pio/Los (80.7 ± 11.4% vs. 50.3 ± 4.2% in UNx + Pio and 57.2 ± 6.5% in UNx + Los) with more apoptotic cells. The expanded macrophage-rich lesions of UNx + Pio/Los had more alternatively activated, Ym-1 and arginine 1-positive M2 phenotypes (Ym-1: 33.6 ± 8.2%, p < 0.05 vs. 12.0 ± 1.1% in UNx; arginase 1: 27.8 ± 0.9%, p < 0.05 vs. 11.8 ± 1.3% in UNx). In vitro, pioglitazone alone and together with losartan was more effective than losartan alone in dampening lipopolysaccharide-induced cytokine production, suppressing M1 phenotypic change while enhancing M2 phenotypic change. CONCLUSION: Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone. This benefit reflects mitigation in macrophage cytokine production, enhanced apoptosis, and a shift toward an anti-inflammatory phenotype.
OBJECTIVE:Chronic kidney disease (CKD) amplifies atherosclerosis, which involves renin-angiotensin system (RAS) regulation of macrophages. RAS influences peroxisome proliferator-activated receptor-γ (PPARγ), a modulator of atherogenic functions of macrophages, however, little is known about its effects in CKD. We examined the impact of combined therapy with a PPARγ agonist and angiotensin receptor blocker on atherogenesis in a murine uninephrectomy model. METHODS:Apolipoprotein E knockout mice underwent uninephrectomy (UNx) and treatment with pioglitazone (UNx + Pio), losartan (UNx + Los), or both (UNx + Pio/Los) for 10 weeks. Extent and characteristics of atherosclerotic lesions and macrophage phenotypes were assessed; RAW264.7 and primary peritoneal mouse cells were used to examine pioglitazone and losartan effects on macrophage phenotype and inflammatory response. RESULTS:UNx significantly increased atherosclerosis. Pioglitazone and losartan each significantly reduced the atherosclerotic burden by 29.6% and 33.5%, respectively; although the benefit was dramatically augmented by combination treatment which lessened atherosclerosis by 55.7%. Assessment of plaques revealed significantly greater macrophage area in UNx + Pio/Los (80.7 ± 11.4% vs. 50.3 ± 4.2% in UNx + Pio and 57.2 ± 6.5% in UNx + Los) with more apoptotic cells. The expanded macrophage-rich lesions of UNx + Pio/Los had more alternatively activated, Ym-1 and arginine 1-positive M2 phenotypes (Ym-1: 33.6 ± 8.2%, p < 0.05 vs. 12.0 ± 1.1% in UNx; arginase 1: 27.8 ± 0.9%, p < 0.05 vs. 11.8 ± 1.3% in UNx). In vitro, pioglitazone alone and together with losartan was more effective than losartan alone in dampening lipopolysaccharide-induced cytokine production, suppressing M1 phenotypic change while enhancing M2 phenotypic change. CONCLUSION: Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone. This benefit reflects mitigation in macrophage cytokine production, enhanced apoptosis, and a shift toward an anti-inflammatory phenotype.
Authors: Eisuke Suganuma; Yiqin Zuo; Nobuhiko Ayabe; Ji Ma; Vladimir R Babaev; Macrae F Linton; Sergio Fazio; Iekuni Ichikawa; Agnes B Fogo; Valentina Kon Journal: J Am Soc Nephrol Date: 2005-12-21 Impact factor: 10.121
Authors: Daniel Teupser; Ralph Burkhardt; Wolfgang Wilfert; Ivonne Haffner; Klaus Nebendahl; Joachim Thiery Journal: Arterioscler Thromb Vasc Biol Date: 2005-11-10 Impact factor: 8.311
Authors: Bakhtawar K Mahmoodi; Caroline S Fox; Brad C Astor; Robert G Nelson; Kunihiro Matsushita; Josef Coresh Journal: Lancet Date: 2013-02-16 Impact factor: 79.321
Authors: Satoko Arai; John M Shelton; Mingyi Chen; Michelle N Bradley; Antonio Castrillo; Angie L Bookout; Puiying A Mak; Peter A Edwards; David J Mangelsdorf; Peter Tontonoz; Toru Miyazaki Journal: Cell Metab Date: 2005-03 Impact factor: 27.287
Authors: Vladimir R Babaev; Patricia G Yancey; Sergey V Ryzhov; Valentina Kon; Matthew D Breyer; Mark A Magnuson; Sergio Fazio; MacRae F Linton Journal: Arterioscler Thromb Vasc Biol Date: 2005-06-09 Impact factor: 8.311
Authors: Jianyong Zhong; Hai-Chun Yang; Valery Yermalitsky; Elaine L Shelton; Tadashi Otsuka; Carrie B Wiese; Linda S May-Zhang; Babak Banan; Naji Abumrad; Jiansheng Huang; Ashley B Cavnar; Annet Kirabo; Patricia G Yancey; Agnes B Fogo; Kasey C Vickers; MacRae F Linton; Sean S Davies; Valentina Kon Journal: Kidney Int Date: 2021-06-05 Impact factor: 18.998
Authors: Amanda Croasdell; Parker F Duffney; Nina Kim; Shannon H Lacy; Patricia J Sime; Richard P Phipps Journal: PPAR Res Date: 2015-12-02 Impact factor: 4.964